M&A narrative gains momentum
We are reiterating our Buy rating on the back of the strong phase III results released Tuesday evening, which we view as a clear bull case for the company. We raise our target price to EUR68 (from EUR27), reflecting an increased probability of approval to 95% (from 70%) for obefazimod in ulcerative
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.